broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-M97302542-001-04-4 | ACH-000945 | NCIH650_LUNG | MTS010 | 1 | 0.982636 | 0.102427 | 0.003696 | 0.991233 | 0.064196 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000945 |
BRD-A25234499-001-19-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.559851 | 15.056458 | -0.273427 | 0.953945 | 3.622405 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000946 |
BRD-A70858459-001-01-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.213713 | 1.309403 | 0.191022 | 0.80342 | 0.912836 | 1.397452 | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000946 |
BRD-A74914197-001-02-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.915222 | 0.47049 | -0.075636 | 0.982404 | 0.223163 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000946 |
BRD-K02113016-001-19-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.674605 | 0.064929 | 0.004968 | 0.821064 | 15,195,255,763,221.115 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000946 |
BRD-K02130563-001-11-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.057811 | 0.2295 | 0.14064 | 0.303216 | 0.003365 | 0.002089 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000946 |
BRD-K03390685-001-01-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.683602 | 1.352254 | -0.078866 | 1 | 0.05665 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000946 |
BRD-K03406345-001-21-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.869219 | 0.087018 | 0.042501 | 0.937001 | 0.183386 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000946 |
BRD-K03765900-001-01-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.20645 | 1.081847 | 0.582695 | 0.86137 | 2.15536 | 3.526228 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000946 |
BRD-K05804044-001-18-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.908011 | -5.149381 | 0.009871 | 0.964133 | 0.026833 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000946 |
BRD-K06814349-304-02-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.002258 | 1.826763 | 0.271296 | 0.923272 | 0.477294 | 0.476118 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000946 |
BRD-K08109215-001-06-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.329275 | -0.25168 | 0.133589 | 0.737206 | 0.011051 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000946 |
BRD-K08542803-001-02-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.044506 | 1.619868 | 0.664478 | 0.603659 | 0.178695 | 0.189282 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000946 |
BRD-K08547377-001-04-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.004052 | 0.436267 | 0.643144 | 0.645453 | 0.498849 | 0.489706 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000946 |
BRD-K08703257-001-13-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.079264 | -0.29631 | -0.052594 | 1 | 0.116439 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000946 |
BRD-K08799216-001-05-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.20045 | 0.316364 | -0.256385 | 0.61366 | 0.100558 | 0.507832 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000946 |
BRD-K11267252-001-05-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.162699 | 0.401239 | -0.095716 | 1 | 0.059504 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000946 |
BRD-K11630072-001-13-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.087532 | 1.843275 | 0.60446 | 0.801119 | 1.219536 | 1.353747 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000946 |
BRD-K12184916-001-19-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.458489 | 2.063412 | 0.38957 | 0.553316 | 0.003202 | 0.010695 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000946 |
BRD-K12343256-001-14-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.141676 | -0.310204 | -0.43977 | 1 | 0.652004 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000946 |
BRD-K13049116-001-04-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.502065 | -0.803615 | 0.136966 | 0.943771 | 0.000939 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000946 |
BRD-K13390322-001-06-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.129403 | 11.966238 | 0.530183 | 0.813618 | 1.252284 | 1.284023 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000946 |
BRD-K13514097-001-04-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.389731 | 0.015223 | -0.052068 | 0.685238 | 0.001233 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000946 |
BRD-K13662825-001-07-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.046987 | 0.546216 | 0.712259 | 0.496906 | 0.014316 | 0.017151 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000946 |
BRD-K14109347-001-03-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.537054 | 0.745236 | 0.137386 | 1 | 0.480499 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000946 |
BRD-K15179879-001-03-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.076881 | 2.751719 | 0.647657 | 0.699228 | 0.423443 | 0.449926 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000946 |
BRD-K15600710-066-05-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.172942 | 4.096013 | 0.695548 | 0.658239 | 0.178011 | 0.197448 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000946 |
BRD-K16730910-001-10-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.807955 | 6.626916 | 0.066693 | 0.93422 | 0.360062 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000946 |
BRD-K17555800-003-02-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.069086 | -0.103948 | -0.010082 | 1 | 14.447264 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000946 |
BRD-K17610631-001-03-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.269637 | 0.911253 | 0.911963 | 0.749611 | 0.365909 | 0.856462 | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000946 |
BRD-K17743125-001-08-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.215647 | 3.852821 | 0.95386 | 0.69064 | 0.217609 | 0.251939 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000946 |
BRD-K17894950-001-14-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.235876 | 0.284677 | 0.034745 | 1 | 0.005722 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000946 |
BRD-K18961567-001-01-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.318617 | 2.005098 | 0.729597 | 0.705282 | 0.150342 | 0.249291 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000946 |
BRD-K19540840-001-09-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.728347 | 0.739126 | 0.021322 | 0.859715 | 0.065999 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000946 |
BRD-K19687926-001-04-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.786341 | 0.975602 | 0.071423 | 0.918847 | 0.257212 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000946 |
BRD-K19796430-001-05-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.849479 | -0.16466 | -0.012349 | 0.938591 | 0.007236 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000946 |
BRD-K22064724-001-01-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.057586 | 0.676688 | 0.442397 | 0.530805 | 0.079866 | 0.095696 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000946 |
BRD-K22822991-001-02-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.959193 | 0.678372 | 0.057741 | 0.978926 | 0.065781 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000946 |
BRD-K23228615-001-02-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.937416 | 0.702838 | -0.019786 | 0.965429 | 0.045333 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000946 |
BRD-K23984367-001-07-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.269514 | 0.199536 | -0.117009 | 1 | 0.019706 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000946 |
BRD-K26026438-001-01-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.339746 | 2.542169 | 0.27256 | 0.91008 | 2.704207 | 4.230853 | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000946 |
BRD-K26657438-001-15-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.330277 | 0.010214 | -0.220364 | 1 | 8,072,732,494,549,693,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000946 |
BRD-K28822270-001-03-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.543704 | 4.669822 | 0.472714 | 0.858541 | 0.516641 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000946 |
BRD-K29905972-001-06-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.795978 | 0.567358 | 0.084294 | 0.899294 | 0.083811 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000946 |
BRD-K30577245-001-05-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.292593 | 2.52578 | 0.111523 | 0.578029 | 0.001913 | 0.00271 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000946 |
BRD-K31698212-001-02-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.932473 | 1.34142 | -0.031694 | 0.97964 | 0.544098 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000946 |
BRD-K31928526-001-02-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.842887 | 0.429006 | 0.032857 | 0.937853 | 0.291275 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000946 |
BRD-K33379087-001-07-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.49687 | 3.697472 | 0.087526 | 0.797199 | 0.200057 | 0.789013 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000946 |
BRD-K33610132-001-02-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.451651 | 0.728237 | 0.18207 | 0.918361 | 26.733661 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000946 |
BRD-K33622447-066-01-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.129343 | 3.408598 | 0.514949 | 0.858648 | 2.071745 | 2.261902 | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000946 |
BRD-K35520305-001-16-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.420836 | 0.001159 | -0.160721 | 0.709416 | 0.000199 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000946 |
BRD-K36788280-001-01-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.773898 | -0.096328 | -0.205664 | 0.906618 | 0.001902 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000946 |
BRD-K37379014-001-02-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.172106 | 0.416309 | 0.392082 | 0.711277 | 0.008665 | 0.023873 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000946 |
BRD-K38332599-001-01-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.137193 | 1.356447 | 0.498579 | 0.770042 | 0.769845 | 0.9752 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000946 |
BRD-K38527262-300-01-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.279374 | 4.24388 | 0.734932 | 0.975218 | 2.311255 | 2.081729 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000946 |
BRD-K38852836-001-02-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.062156 | 1.800205 | 0.862095 | 0.507001 | 0.015245 | 0.016411 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000946 |
BRD-K39974922-001-04-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.967926 | -0.025567 | -0.000217 | 0.982986 | 9.273973 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000946 |
BRD-K41859756-001-06-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.168734 | 4.553736 | 0.750361 | 0.406018 | 0.00244 | 0.002671 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000946 |
BRD-K42495768-001-01-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.664833 | 1.185199 | 0.524885 | 0.882899 | 0.341911 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000946 |
BRD-K42805893-001-04-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.129774 | 1.277815 | 0.269033 | 0.79245 | 1.03014 | 1.303245 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000946 |
BRD-K42828737-001-03-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.847072 | -6.957659 | 0.321327 | 0.910548 | 0.079152 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000946 |
BRD-K42898655-001-01-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.305261 | 0.30954 | 0.318495 | 0.619651 | 0.00236 | 0.049647 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000946 |
BRD-K43389675-001-02-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.017636 | 0.757576 | 0.585417 | 0.485432 | 0.061247 | 0.06422 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000946 |
BRD-K44227013-001-06-4 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.156635 | 1.920169 | 0.712491 | 0.770313 | 0.713787 | 0.868081 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000946 |
BRD-K44408410-001-17-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.852501 | 0.13474 | 0.008861 | 0.914584 | 0.006733 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000946 |
BRD-K44827188-001-06-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.567355 | 0.08649 | -0.066064 | 1 | 0.092457 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000946 |
BRD-K46386702-001-02-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.840272 | -3.729941 | 0.15866 | 0.91484 | 0.10775 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000946 |
BRD-K49328571-001-15-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.248875 | 0.923177 | 0.541966 | 0.50269 | 0.015396 | 0.032463 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000946 |
BRD-K49350383-001-14-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.90142 | 0.006039 | -0.006586 | 0.950395 | 0.009385 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000946 |
BRD-K50010139-001-01-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.503308 | 0.645025 | -0.094975 | 0.829 | 0.417557 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000946 |
BRD-K50168500-001-07-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | -0.181211 | 0.288736 | -0.158766 | 0.562937 | 0.655824 | 0.224707 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000946 |
BRD-K51313569-001-07-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.526354 | 1.456032 | 0.761156 | 0.737361 | 0.045974 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000946 |
BRD-K51791723-003-01-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.13658 | 6.28032 | 0.644225 | 0.710825 | 0.387641 | 0.407843 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000946 |
BRD-K51967704-001-03-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.1094 | 2.46979 | 0.751487 | 0.707852 | 0.414485 | 0.458067 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000946 |
BRD-K52313696-001-12-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.039034 | 1.229773 | 0.533604 | 0.855363 | 2.689661 | 2.873502 | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000946 |
BRD-K53414658-001-08-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.166957 | -0.390153 | -0.02237 | 1 | 0.020303 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000946 |
BRD-K53972329-001-07-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.138684 | -0.150935 | 0.025045 | 1 | 1.024654 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000946 |
BRD-K54955827-001-02-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.140958 | 5.675044 | 0.077491 | 1 | 0.00487 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000946 |
BRD-K54997624-001-06-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 3.811454 | 1.466777 | 0.789365 | 1 | 7.812135 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000946 |
BRD-K55187425-236-05-2 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.081676 | 0.607514 | 0.386538 | 0.442067 | 0.024271 | 0.032552 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000946 |
BRD-K56343971-001-14-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.60316 | 0.396846 | 0.0008 | 0.823749 | 0.161981 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000946 |
BRD-K56981171-001-02-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.876187 | 1.145061 | 0.118775 | 0.951506 | 0.225795 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000946 |
BRD-K57080016-001-15-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.650694 | -1.945918 | -0.057266 | 1 | 0.000576 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000946 |
BRD-K57169635-001-04-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.468081 | -0.010368 | -0.020532 | 0.733306 | 0.133109 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000946 |
BRD-K58435339-001-03-0 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.028381 | 0.523601 | 0.419613 | 0.520898 | 0.084478 | 0.094452 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000946 |
BRD-K58529924-001-01-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.180215 | 5.371073 | 0.80951 | 0.940336 | 5.250556 | 5.706184 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000946 |
BRD-K58550667-001-08-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.159018 | 6.928389 | 0.63488 | 0.626494 | 0.008392 | 0.008869 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000946 |
BRD-K59317601-001-05-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.394599 | 4.260979 | 0.645545 | 0.720313 | 0.112949 | 0.162765 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000946 |
BRD-K59369769-001-22-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.775845 | 0.770965 | -0.024398 | 0.873657 | 0.04082 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000946 |
BRD-K60866521-001-07-1 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.131291 | -0.408676 | -0.088329 | 1 | 2.768439 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000946 |
BRD-K60997853-001-02-3 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.097054 | 5.641399 | 0.71968 | 0.857408 | 2.159916 | 2.244152 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000946 |
BRD-K61192372-001-08-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.987412 | -0.303949 | 0.001044 | 0.99722 | 0.000653 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000946 |
BRD-K62008436-001-23-9 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.086786 | 0.42407 | 0.613216 | 0.47611 | 0.001927 | 0.00302 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000946 |
BRD-K62196610-001-01-6 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.409836 | 3.702359 | 0.534301 | 0.82536 | 0.565991 | 0.898983 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000946 |
BRD-K62200014-003-10-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.821082 | 1.156073 | 0.364987 | 0.910383 | 0.077433 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000946 |
BRD-K62391742-001-09-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.028766 | -0.473557 | -0.174143 | 1 | 0.127623 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000946 |
BRD-K62627508-001-01-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.080686 | 5.553363 | 0.902043 | 0.69215 | 0.387827 | 0.400307 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000946 |
BRD-K63712959-001-01-8 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.774833 | -0.22819 | -0.005472 | 0.870144 | 0.346524 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000946 |
BRD-K64052750-001-22-5 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 1.135021 | -0.778418 | -0.237374 | 1 | 0.034154 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000946 |
BRD-K64881305-001-03-7 | ACH-000946 | HEC265_ENDOMETRIUM | MTS010 | 1 | 0.249568 | 0.59648 | 0.442876 | 0.57931 | 0.040422 | 0.128835 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000946 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.